The quest for a disease-free world has gained momentum over the years with various organizations and individuals coming up with innovative and effective ways of attaining this noble and all-important goal. One such ways is open access to vital research information on various diseases including cancer and other medical conditions and scientific topics. Established in 2010, Oncotarget has added to the growing impetus for a world truly liberated from the clutches of diseases.
Promoting Research Beyond Oncology
When it was established, Oncotarget primarily focused on cancer. The weekly medical journal published Impact Journal received and peer-reviewed the submitted research articles before publishing them for consumptions. However, over the years it has adopted a strategic approach that is reflective of its mission of ensuring disease-free world. It has broadened the scope of the articles it accepts, which has seen new fields added to oncology. The Gordon Research Conference-sponsored journal accepts articles focusing on cellular biology, endocrinology, neuroscience, cardiology and metabolism among others. This comprehensive approach, open access platform and multiple peer review process conducted by its multidiscipline peer review team and editors have played important role in the growing popularity of the journal.
Growing Popularity within the Scientific Community
A year after its establishment by Mikhail Blagosklonny and Andrei V. Gudkov, Oncotarget had an Impact Factor of 4.784 after it was cited 493 times. Since then, the journal’s reputation has grown exponentially to become one of the most cited journals in the scientific community. Recently, Thomson Reuters JCR released the latest Impact Factor (IF) figures for the assessment year 2016/2017, which show that Oncotarget has been cited a staggering 30,241 times. This translates to an IF of 5.168, which is the highest in the journals history and one of the best in the scientific community. When compared to the IF figures released for the 2015/2016 assessment year, the new citation figures has almost tripled as Oncotarget was cited 10,452 times. Additionally, it is the number one journal globally according to the latest journal Factor(IF) rankings based on published articles released in 2015. Scopus/SJR gave the journal a QI ranking, which is the highest rank.
Drivers of Success: Commitment Towards Quality
Oncotarget has over 100 peer reviewers who are highly experienced and qualified professionals drawn from various fields that the journal’s articles specialize in. These reviews ensure that the articles submitted for publications meet the required validation and quality standards. Moreover, the journal’s editorial board is comprised of several highly qualified professionals with vast experience in various fields. Professor Mikhail Blagosklonny currently serves as the founding editor-in-chief of the journal. He shares the role with Andrei V. Gudkov.